363 related articles for article (PubMed ID: 17478055)
1. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.
Kung VW; Hassam R; Morton AJ; Jones S
Neuroscience; 2007 Jun; 146(4):1571-80. PubMed ID: 17478055
[TBL] [Abstract][Full Text] [Related]
2. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
Gibson HE; Reim K; Brose N; Morton AJ; Jones S
Eur J Neurosci; 2005 Oct; 22(7):1701-12. PubMed ID: 16197510
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 receptors and group I metabotropic glutamate receptors contribute to the induction of long-term potentiation in the nucleus accumbens.
Schotanus SM; Chergui K
Neuropharmacology; 2008 Apr; 54(5):837-44. PubMed ID: 18272187
[TBL] [Abstract][Full Text] [Related]
4. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
[TBL] [Abstract][Full Text] [Related]
6. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
Johnson MA; Rajan V; Miller CE; Wightman RM
J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
J Neurochem; 2010 Feb; 112(3):755-61. PubMed ID: 19929911
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
9. Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease.
Ghiglieri V; Campanelli F; Marino G; Natale G; Picconi B; Calabresi P
J Neurosci Res; 2019 Dec; 97(12):1655-1664. PubMed ID: 31498496
[TBL] [Abstract][Full Text] [Related]
10. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
11. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.
Vetter JM; Jehle T; Heinemeyer J; Franz P; Behrens PF; Jackisch R; Landwehrmeyer GB; Feuerstein TJ
J Neurochem; 2003 May; 85(4):1054-63. PubMed ID: 12716437
[TBL] [Abstract][Full Text] [Related]
12. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
13. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease.
Cummings DM; Milnerwood AJ; Dallérac GM; Waights V; Brown JY; Vatsavayai SC; Hirst MC; Murphy KP
Hum Mol Genet; 2006 Oct; 15(19):2856-68. PubMed ID: 16905556
[TBL] [Abstract][Full Text] [Related]
14. Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro.
Navakkode S; Sajikumar S; Frey JU
Neuropharmacology; 2007 Jun; 52(7):1547-54. PubMed ID: 17433377
[TBL] [Abstract][Full Text] [Related]
15. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
16. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.
Giralt A; Rodrigo T; Martín ED; Gonzalez JR; Milà M; Ceña V; Dierssen M; Canals JM; Alberch J
Neuroscience; 2009 Feb; 158(4):1234-50. PubMed ID: 19121372
[TBL] [Abstract][Full Text] [Related]
17. MPTP modulates hippocampal synaptic transmission and activity-dependent synaptic plasticity via dopamine receptors.
Zhu G; Huang Y; Chen Y; Zhuang Y; Behnisch T
J Neurochem; 2012 Aug; 122(3):582-93. PubMed ID: 22651101
[TBL] [Abstract][Full Text] [Related]
18. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
19. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
[TBL] [Abstract][Full Text] [Related]
20. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation.
Dallérac GM; Vatsavayai SC; Cummings DM; Milnerwood AJ; Peddie CJ; Evans KA; Walters SW; Rezaie P; Hirst MC; Murphy KP
Neurodegener Dis; 2011; 8(4):230-9. PubMed ID: 21282937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
